Supplemental material
Journal of Medical Economics
Volume 25, 2022 - Issue 1
Hematology
Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors
, 
, , , , , & show all
Adina Estrinc Scientific Engagement, Aetion, Inc, New York, NY, USAhttps://orcid.org/0000-0001-8866-2911
https://orcid.org/0000-0001-8866-2911, , David Hindsd BioMarin Pharmaceuticals, Inc, San Rafael, CA, USAhttps://orcid.org/0000-0003-0219-9941
https://orcid.org/0000-0003-0219-9941, Patricia Princec Scientific Engagement, Aetion, Inc, New York, NY, USAhttps://orcid.org/0000-0002-0705-6942
https://orcid.org/0000-0002-0705-6942, Jennifer Thorburnc Scientific Engagement, Aetion, Inc, New York, NY, USAhttps://orcid.org/0000-0003-2417-610X
https://orcid.org/0000-0003-2417-610X, Henry Meadd BioMarin Pharmaceuticals, Inc, San Rafael, CA, USAhttps://orcid.org/0000-0002-6599-7142
https://orcid.org/0000-0002-6599-7142 & Christine L. Kemptona Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA;b Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA, USAhttps://orcid.org/0000-0002-2391-2016
https://orcid.org/0000-0002-2391-2016 show allRelated Research Data
Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult male people with Hemophilia A without inhibitors
Source:
Taylor & Francis
Linking provided by
